Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis

Guilherme Simpione 1, Rogério J. Caldas 2, Mariana Q. S. Soares 3, Izabel R. F. Rubira-Bullen 4, Paulo S. S. Santos 4

1 Master student, Bauru School of Dentistry, University of Sao Paulo, Brazil
2 PhD, Bauru School of Dentistry, University of Sao Paulo, Brazil
3 Post-doctoral student Bauru School of Dentistry, University of Sao Paulo, Brazil
4 Associate Professor, Department of Surgery, Stomatology, Radiology and Pathology, Faculty of Dentistry of Bauru – USP

Correspondence:
Bauru School of Dentistry - University of Sào Paulo (FOD-USP)
Department of Surgery, Stomatology
Pathology and Radiology
Alameda Octávio Pinheiro Brisola
9-75, Vila Universitária
ZIP CODE: 17012-901 Bauru-SP / Brazil
paurosss@fob.usp.br

Received: 04/09/2019
Accepted: 08/01/2020

Abstract
Background: Bisphosphonates (BP) are synthetic pyrophosphate-like substances with antiresorptive properties and specifically affect osteoclastic activity. In 2007, the American Association of Oral and Maxillofacial Surgeons (AAOMS) defined diagnostic criteria for Osteonecrosis of the Jaws Associated with Bisphosphonates (BRONJ). BRONJ is mainly diagnosed by clinical features, but the detection of early bone changes by imaging may help prevent and better understand the disease. The objective of this study was to evaluate maxillary changes in CBCT in patients using BP.

Material and Methods: All included patients were diagnosed with osteonecrosis and received bisphosphonate drugs in the last ten years. All imaging examinations were obtained by I-CAT and 3D Accuitomo. The multiplanar reconstructions were analyzed by an examiner without knowledge of the clinical aspects and location of the lesions.

Results: The study sample consisted of 21 patients, the majority of the sample represented patients with cancer (76.2%), the other patients had osteoporosis (23.8%). Only four patients (19.04%) received alendronate, while intravenous bisphosphonates, such as zoledronate and pamidronate, represented the treatment of most of our sample. Most of our patients presented stage 1 and 2 MRONJ (85.7%), whose lesions were mainly observed in the mandible (52.4%). Fifty-seven percent of the patients had at least one bone change.

Conclusions: In BRONJ, bone changes vary between exposed and non-exposed areas and one aspect of the study was: persistent extraction cavities in the BRONJ lesion region and high frequency of periodontal ligament space widening in areas that are not involved in BRONJ lesions. This reflects the very important role of dental and periodontal diseases in the pathophysiology of BRONJ. Thus, preventive measures should be prioritized for patients exposed to anti-resorptive drugs.

Key words: Cone-Beam computed tomography, osteonecrosis, bisphosphonate-associated osteonecrosis of the jaw.
Introduction

Bisphosphonates (BP) are non-metabolic, synthetic, pyrophosphate-like substances with anti-resorptive properties. These drugs are indicated for several bone diseases such as: osteoporosis, Paget’s disease, hypercalcemia of malignant tumors, bone metastases and multiple myeloma(1,2). BP specifically affect osteoclastic activity, decreasing the number of osteoclasts by apoptosis induction. Consequently, the bone turnover is compromised. (3). In 2007, the American Association of Oral and Maxillofacial Surgeons (AAOMS) defined diagnostic criteria for BRONJ: current or previous BP treatment, exposed bone in the maxillofacial region that persisted for more than 8 weeks, and no history radiotherapy in the maxillary region (1). In 2014, AAOMS issued an updated paper on this topic (4). The intake of nitrogen-containing BP and the presence of local infection are known as the main risk factors for the disease. BRONJ is diagnosed primarily by clinical features, but radiological examinations are crucial to rule out hypotheses of other diseases as well as to evaluate the stage and extent of disease (5). The detection of early bone changes by means of radiographic imaging could help preventing and better understanding the disease. Therefore, the objective of this study is to evaluate changes in CBCT jawbones under the influence of bisphosphonates.

Material and Methods

This study was approved by the Ethics Committee on Human Research of our institution (protocol number 1.959.558). All patients included were diagnosed with BRONJ in accordance with the AAOMS diagnostic and staging criteria (6). Only patients who received bisphosphonate drugs in the past ten years were included in this research. Data regarding clinical aspects of BRONJ, sex, age and medical history were obtained from patients’ charts. The imaging exams were obtained with i-CAT (Xoran Technologies, Ann Arbor, Mich., And Imaging Sciences International, Hatfield, PA) and 3D Accuitomo XYZ Slice View Tomograph (J. Morita, Kyoto, Japan). CT scans with field of views including the entire maxilla, or mandible or both were included for analysis. Multiplanar reconstructions were analyzed by one examiner unaware of the clinical aspects and location of the lesions. The presence of osteosclerosis, which is characterized by hyperdense images on CBCTs, laminae dura thickening without endodontics association, maxillary sinus cortical thickening, maxillary sinus alteration, bone sequestrum, bone resorption in the jaws, persistent extraction socket, and discontinuation of the maxillary sinus floor, cortical mandibular and cortical mandibular canal were identified and quantified separately for each quadrant. Each tomographic finding was evaluated for its presence in relation to the clinical location of the lesion: if it was present in the region (quadrant) of the lesion, in another quadrant, or present in both. The frequency of bone changes in each quadrant was quantified. Statistical analysis were performed by IBM SPSS Statistics 17 software for Windows. Chi-squared test was applied to verify the association between the bone changes and MRONJ stage, and the significance level was set at 5%.

Results

The study sample consisted of 21 patients (Table 1). Of those, 23.8% correspond to men and 76.2% to women. Considering the diagnosis, most of the sample represented cancer patients (76.2%). The remaining patients suffered from osteoporosis (23.8%). Diabetes was also a comorbidity seen in five patients. Concerning risk factors for BRONJ, the use of corticosteroids was observed in 28.6% of the patients and seven patients (33.3%) had previous history of a recent dental extraction. A long-term bisphosphonate therapy (more than 3 years) was found in 57.1% of the patients. Only four patients (19.04%) received alendronate, while intravenous bisphosphonate such as zoledronate and pamidronate represented the treatment of the majority of our sample. Most of our patients presented with stage 1 and 2 BRONJ (85.7%), whose lesions were mainly seen in the mandible (52.4%). Dental implants as well as remaining tooth root were uncommonly seen in the area of BRONJ lesions (4.8%).

As bone changes, all of the following could be observed: widening of the periodontal ligament space without endodontics association, thickened laminae dura, maxillary sinus cortical thickening, maxillary sinus alteration, thickening of the mandibular cortical, thickening of the mandibular canal cortical, osteosclerosis, bone sequestrum, bone resorption, persistent extraction socket, and discontinuation of the maxillary sinus floor (Table 2). In 57% of the patients one or more bone alterations were present in the lesion region and in another region. Differences among the quadrant of BRONJ lesions and the others could be detected. In the region of BRONJ lesions, the most frequent bone changes were bone sequestrum (52.4%), persistent extraction socket (42.9%) and osteosclerosis (28.6%). On the other hand, changes such as widening of periodontal ligament space (33.3%) and maxillary sinus alteration (23.8%) followed by thickened mandibular canal cortical (19%) and bone resorption (19%) were the most recurrent in the other quadrants. Concerning the less common bone changes, a thickened lamina dura and maxillary sinus cortical were characteristics of quadrants with and without BRONJ lesion. While bone resorption could be barely seen near BRONJ lesions, bone sequestrum could be rarely noted in non-affected quadrants.
Table 1: Clinical and prospective data from 21 patients.

| Age | Sex | Diagnosis          | Medication            | Months | Usage         | MRONJ Site                     | Recent extraction | Stage |
|-----|-----|--------------------|-----------------------|--------|--------------|--------------------------------|--------------------|-------|
| 1   | 70  | F                  | Breast Cancer         | Zoledronate | 12 | Intravenous  | Left Palate                   | No                 | 2     |
| 2   | 74  | F                  | Breast Cancer         | Zoledronate | 11 | Intravenous  | Left Mandible                 | No                 | 0     |
| 3   | 47  | F                  | Breast Cancer         | Zoledronate | 108| Intravenous  | Left Mandible                 | No                 | 1     |
| 4   | 60  | F                  | Breast Cancer         | Zoledronate | 48 | Intravenous  | Left and Right Maxilla         | No                 | 1     |
| 5   | 79  | M                  | Multiple myeloma      | Zoledronate | 36 | Intravenous  | Left and Right Maxilla and Left Mandible | Yes               | 3     |
| 6   | 78  | F                  | Osteoporosis          | Alendronate  | 120| Oral          | Right Maxilla                 | No                 | 2     |
| 7   | 57  | F                  | Breast Cancer         | Pamidronate / Zoledronate | 24 | Intravenous  | Left Mandible                 | No                 | 2     |
| 8   | 66  | F                  | Osteoporosis          | Alendronate  | 120| Oral          | Right Maxilla                 | No                 | 3     |
| 9   | 42  | F                  | Breast Cancer         | Pamidronate  | 168| Intravenous  | Right Mandible                 | Yes               | 2     |
| 10  | 92  | M                  | Prostate Cancer       | Zoledronate  | 48 | Intravenous  | Right Maxilla                 | No                 | 2     |
| 11  | 80  | F                  | Breast Cancer         | Zoledronate  | 84 | Intravenous  | Right Maxilla                 | No                 | 1     |
| 12  | 72  | F                  | Kidney Cancer         | Zoledronate  | 12 | Intravenous  | Left and Right Mandible       | No                 | 1     |
| 13  | 68  | F                  | Osteoporosis          | Alendronate  | 72 | Oral          | Right Maxilla                 | No                 | 1     |
| 14  | 58  | F                  | Breast Cancer         | Zoledronate  | 60 | Intravenous  | Left Mandible                 | No                 | 2     |
| 15  | 79  | F                  | Osteoporosis          | Alendronate  | 72 | Oral          | Left and Right Mandible       | No                 | 1     |
| 16  | 84  | F                  | Osteoporosis          | Zoledronate / Ibandronate | 120| Intravenous / Oral | Left and Right Maxilla       | No                 | 1     |
| 17  | 62  | M                  | Prostate Cancer       | Zoledronate  | 14 | Intravenous  | Left Mandible                 | Yes               | 1     |
| 18  | 70  | M                  | Multiple myeloma      | Zoledronate  | 18 | Intravenous  | Right Mandible                 | Yes               | 1     |
| 19  | 66  | F                  | Breast Cancer         | Pamidronate  | 60 | Intravenous  | Left Maxilla                  | Yes               | 1     |
| 20  | 68  | F                  | Breast Cancer         | Zoledronate  | 18 | Intravenous  | Right Mandible                 | Yes               | 1     |
| 21  | 63  | M                  | Colon Cancer          | Pamidronate  | 08 | Intravenous  | Right Mandible                 | Yes               | 1     |

Discussion
This work identified jaw bone changes among patients with BRONJ, describing tomographic findings in regions with BRONJ lesions as well as in the non-affected ones. These areas without established BRONJ lesion might reveal changes correspondent to effects of the antiresorptive drugs on bone. Comparing both regions, it was expected to find out alterations in bone that could point out early signs of BRONJ. In fact, this study showed tomographic signs near BRONJ lesions that were absent in non-affected sites and vice versa. Interestingly, Guo et al. could not detect any changes in the bony architecture.
Table 2: Prevalence of jaw changes on cone beam computed tomography.

|                                     | Present in the region of the lesion | Present in other region | Present in both regions | Absent | Undefined |
|-------------------------------------|-------------------------------------|-------------------------|-------------------------|--------|-----------|
| Widenig of the periodontal ligament space | 19%                   | 33,3%                  | 19%                     | 28,6%  | -         |
| Laminae dura thickening             | 4,8%                  | 4,8%                   | -                       | 90,5   | -         |
| Maxilar sinus cortical thickening    | 14,3%                 | 4,8%                   | -                       | 61,9%  | 19%       |
| Maxilar sinus alteration             | 23,8%                 | 23,8%                  | 14,3%                   | 19%    | 19%       |
| Thickenig of the mandibular cortical | 23,8%                 | 9,5%                   | 23,8%                   | 33,3%  | 9,5%      |
| Thickening of the mandibular canal cortical | 23,8% | 19%                 | 4,8%                    | 42,9%  | 9,5%      |
| Osteosclerosis                      | 28,6%                 | 9,5%                   | 33,3%                   | 28,6%  | -         |
| Presence of bone sequestrum         | 52,4%                 | 4,8%                   | -                       | 42,9%  | -         |
| Presence of Implants                | 4,8%                  | 14,3%                  | 4,8%                    | 76,2%  | -         |
| Presence of bone resorption         | 4,8%                  | 19%                    | 47,6%                   | 28,6%  | -         |
| Presence of persistent alveolus      | 42,9%                 | 9,5%                   | -                       | 47,6%  | -         |
| Presence of bone chages             | 33,3%                 | -                      | 57,1%                   | 9,5%   | -         |
| Discontinuation of the maxillary sinus floor | 4,8% | 9,5%             | -                       | 85,7%  | -         |
| Remaining tooth root                | 4,8%                  | 4,8%                   | -                       | 90,5%  | -         |

on the non-osteonecrosis sites in the same patients with BRONJ by CBCT.

Even though studies on imaging of BRONJ have been conducted, none have contributed to determine early diagnosis of this condition (7). Their conclusions are even contradictory. Some researches postulated that the first evidence of BRONJ would be osteosclerosis and an active bone resorption would be present at advanced stages (8–12). Others claimed that the degree of sclerosis might increase as clinical severity of the condition progressed (13–16). In the present study, osteosclerosis was very frequent in BRONJ quadrants but not in non-compromised sites, so that it seemed to be related to advanced BRONJ stages. Nonetheless, Wilde et al. presumed that this sign is generally insignificant in indicating the severity and extent of the BRONJ lesion, since it was irregularly distributed across all BRONJ stages in their study. Actually, the presence of osteosclerosis in clinically symptomatic areas of the jaws has been described as a consistent tomographic finding, both in initial and advanced forms of osteonecrosis (14,17).

Besides sclerosis, osteolysis and sequestrum formation were frequent findings in stage 1 and 2 BRONJ, and universal in Stage 3 BRONJ (11,17). Corroborating these outcomes, our work showed that bone sequestrum was markedly a common finding near BRONJ lesions and the less recurrent one in other regions, but bone resorption could be frequently noted in all areas. However, these well-recognized tomographic features have not been found consistently and have been mainly associated with advanced stages of this disease (12,14).

Also, thickening of the lamina dura and alveolar crest have been considered as the most common radiographic features in patients taking bisphosphonate (12,18). They might indicate a higher risk for BRONJ and have been related to its early stages (9,10,12,19). Differently, a thickened lamina dura was hardly found near MRONJ lesions and in non-affected sites in our study. However, we could often see a widening of periodontal ligament space in areas other than involved in BRONJ lesions. Associated with the high frequency of persistent extraction sockets (42.9%) in the region of BRONJ lesions also observed in our study, a main role of dental and periodontal diseases in the development of BRONJ could be unveiled for our sample. This is in line with recent outcomes evidenced by a systematic review (7).

A significant increase in mandibular cortical thickness was verified by CBCT in case-control studies (16,20,21). Confirming these data, two retrospective studies assessed the mandibular cortical width by comparing CBCTs obtained from patients with BRONJ, patients under antiresorptive therapy without symptoms of BRONJ and patients without history of antiresorptive medication use and symptoms of BRONJ (22,23). Their results pointed out a significant difference in cortical bone width between BRONJ and control groups, but no correlation
could be found between non-BRONJ and control categories. Additionally, the low interobserver reliability between the two observers is a major bias in one of these studies. Another case-control study (24) evaluating the mandibular cortical width and the height from the inferior mandibular border to the mental foramen in 46 Caucasian women receiving oral bisphosphonates without BRONJ demonstrated that both measurements should not be used to predict the risk of this condition. Our study revealed a thickened mandibular cortical bone near BRONJ lesions and even in other areas. In other words, mandibular cortical thickness is a measurement that hardly differentiate patients taking antiresorptive agents without BRONJ from other groups. Consequently, it is challenging to predict the incidence of BRONJ using only this parameter.

A thickened mandibular cortical canal has been advocated as an early sign of BRONJ (7,12). Nonetheless, it was a recurrent sign in areas with and without osteonecrosis in the present study. A case-control study measured the diameter and width of mental foramen as well as the diameter of incisive canal, and just the narrowing of incisive canal was observed in patients with BRONJ (21). This sign was deemed late as a result of progressive sclerotic changes (9,25).

The formation of new periosteal bone could not be found in the present study. As it has been detected in advanced BRONJ stage (9,12,14,15), this might reflect the only two patients at BRONJ stage 3. The involvement of maxilla in our study manifested mainly as maxillary sinus alteration which was a common finding in areas with and without osteonecrosis. The thickening of maxillary sinus cortical was more recurrent in BRONJ areas. These maxillary manifestations were characteristics of middle to advanced BRONJ stages (9,12,14).

Finally, we acknowledge certain limitations to this study. First, we must admit that this study reveals the disadvantages of retrospective studies only with tomographic analysis without clinical features, and second, we must address the problems of single-center BRONJ studies in general. Additionally, we consecutively included 16 female patients and only 5 male patients with BRONJ in our study, leading to a marked female majority in our patient population. Although jaw bones of both genders might be considered as equally susceptible to side effects from bisphosphonate treatment, subtle gender-specific differences could not be ruled out with certainty.

In BRONJ, bone alterations vary greatly in exposed and unexposed in intraoral areas and most of them can be seen throughout all stages of the disease. However, one aspect of the present study should call our attention: the combination of high frequency of persistent extraction sockets in the region of BRONJ lesions and high frequency of widening of periodontal ligament space in areas other than involved in BRONJ lesions. This reflects the very important role in preventing dental and periodontal diseases (dental and periodontal tissues) in patients with or at risk of developing BRONJ. Thus, preventive measures should be prioritized for patients exposed to anti-resorptive drugs.

References
1. Nisi M, Karapetsa D, Genni S, Ramaglia L, Graziani F, Gabriele M. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. J Cranio-Maxillofac Surg. 2018;46:1153-8.
2. Shibahara T, Morikawa T, Yago K, Kishimoto H, Imai Y, Kurita K. National Survey on Bisphosphonate-Related Osteonecrosis of the Jaws in Japan. J Oral Maxillofac Surg. 2018;76:2105-12.
3. Hong JW, Nam W, Cha IH, Chung SW, Choi HS, Kim KM, et al. Oral bisphosphonate-related osteonecrosis of the jaw: The first report in Asia. Osteoporos Int. 2010;21:847-53.
4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Merchotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg. 2014;72:1938-56.
5. Marx RE, Cillo JE, Ulloa JJ. Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment. J Oral Maxillofac Surg. 2007;65:2397-410.
6. Chang JI, Hazboun RC, Chang TL. Incongruities in the AAOMS Position Paper: Medication-Related Osteonecrosis of the Jaw-2014 Update. J Oral Maxillofac Surg. 2014;72:2281.
7. Devlin H, Greenwall-Cohen J, Benton J, Goodwin TL, Littlewood A, Horner K. Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis. Br Dent J. 2018;224:26-31.
8. Barragan-Adjemian C, Lausten L, Ang DB, Johnson M, Katz J, Bonewald LF. Bisphosphonate-related osteonecrosis of the jaw: Model and diagnosis with cone beam computerized tomography. Cells Tissues Organs. 2008;189:284-8.
9. Olutayo J, Aghaje JO, Jacobs R, Verhaeghe V, Velde F Vande, Vincieri F. Bisphosphonate-Related Osteonecrosis of the Jaw Bone: Radiological Pattern and the Potential Role of CBCT in Early Diagnosis. J Oral Maxillofac Res. 2010;1:1-9.
10. Teister NS, Friedland B, Woo S Bin. Use of cone-beam computed tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology. 2010;109:753-64.
11. Wilde F, Heufelder M, Lorenz K, Liese S, Liese J, Helmrich J, et al. Prevalence of cone beam computed tomography imaging findings according to the clinical stage of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114:804-11.
12. Guo Y, Wang D, Wang Y, Peng X, Guo C. Imaging features of medicine-related osteonecrosis of the jaws: comparison between panoramic radiography and computed tomography. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:e69-76.
13. Torres SR, Chen CSK, Leroux BG, Lee PP, Hollinger LD, Schubert MM. Fractal dimension evaluation of cone beam computed tomography in patients with bisphosphonate-associated osteonecrosis. Dentomaxillofacial Radiol. 2011;40:501-5.
14. Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, et al. Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg. 2014;52:603-8.
15. Guggenberger R, Koral E, Zemann W, Jacobsen C, Andreiseg K, Metzler P. Cone beam computed tomography for diagnosis of bisphosphonate-related osteonecrosis of the jaw: evaluation of quantitative and qualitative image parameters. Skeletal Radiol. 2014;43:1669-78.
16. Ozcan G, Sekerci AE, Gonen ZB. Are there any differences in mandibular morphology of patients with bisphosphonate-related os-
Tomographic study in patients with bisphosphonate-related osteonecrosis of jaws?: A case-control study. Dentomaxillofacial Radiol. 2016;45:20160047L.

17. Walton K, Grogan TR, Eshaghzadeh E, Hadaya D, Elashoff DA, Aghaloo TL, et al. Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings. Dentomaxillofacial Radiol. 2018;48:20180128.

18. Moeini M, Moeini M, Lotfizadeh N, Alavi M. Radiography finding in the jaws in children taking bisphosphonate. Iran J Pediatr Hematol Oncol. 2013;3:114-8.

19. Ayranci F, Gungormus M, Omezli MM, Gundogdu B. The Effect of Alendronate on Various Graft Materials Used in Maxillary Sinus Augmentation: A Rabbit Study. Iran Red Crescent Med J. 2015;17:e33569.

20. Torres SR, Chen CSDK, Leroux BG, Lee PP, Hollender LG, Santos ECA, et al. Mandibular cortical bone evaluation on cone beam computed tomography images of patients with bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:695-703.

21. Gönen ZB, Asan CV, Zârarsiz G, Kilic E, Alkan A. Osseous changes in patients with medication-related osteonecrosis of the jaws. Dentomaxillofacial Radiol. 2018;47:20170172.

22. Iwata E, Akashi M, Kishimoto M, Kusumoto J, Hasegawa T, Furuod S, et al. Meaning and limitation of cortical bone width measurement with DentaScan in medication-related osteonecrosis of the jaws. Kobe J Med Sci. 2016;62:E114-9.

23. Koo CH, Lee JH. Evaluation of mandibular cortical bone ratio on computed tomography images in patients taking bisphosphonates. Maxillofac Plast Reconstr Surg. 2018;40:17.

24. Diniz-Freitas M, Fernández-Montenegro P, Fernández-Feijoo J, Limeres-Posse J, González-Mosquera A, Vázquez-García E, et al. Mandibular cortical indices on cone-beam computed tomography images in osteoporotic women on treatment with oral bisphosphonates. Gerodontology. 2016;33:155-60.

25. Berg BI, Mueller A, Augello M, Berg S, Jaquiéry C. Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ). Dent J. 2016;4:29.

Acknowledgement

“This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001”. This work was supported by the University of São Paulo (PUB/PAPFE).

Conflict of interest

The authors have declared that no conflict of interest exist.